Biotech Values

[DewDiligence]

Amicus Therapeutics Files For IPO

[They appear to be a serious competitor for GENZ and Shire.]

http://biz.yahoo.com/prnews/070330/clf140.html?.v=5

>>
Friday March 30, 3:37 pm ET

CRANBURY, N.J., March 30 /PRNewswire/- Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. All shares in the offering will be sold by Amicus Therapeutics.

The underwriters for the offering are led by Morgan Stanley & Co. Incorporated and Merrill Lynch & Co., as joint book-runners, with J.P. Morgan Securities Inc., Lazard Capital Markets LLC, and Pacific Growth Equities, LLC acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

...Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The company is currently conducting Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.
<<